mRNA-DC Vaccines_Pipelines_Products & Service_Company Profile: Beijing tricision Biotherapeu

mRNA-DC Vaccines

Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs), capable of processing and presenting antigens via major histocompatibility complex (MHC) class I and II molecules to both the innate and adaptive immune systems. DCs play a central role in initiating and regulating immune responses. Consequently, they have been extensively investigated as a means to stimulate cancer-specific T-cell responses.

mRNA is an attractive vector for delivering tumor antigens to dendritic cells (DCs). DCs can internalize mRN CD8+ A-encoded antigens via electroporation, introducing the mRNA into the cytoplasm, where it is translated into protein. The protein is then processed into peptides and presented on the cell surface toT cells.

Survivin-Targeting Dendritic Cell (DC) Cell Injection

First mRNA-DC Cancer Therapeutic Vaccine to Receive IND Approval in 2023
This technology has advanced to Phase II clinical trials — the first of its kind in China — benchmarking against global frontrunners, with breakthrough outcomes in both long-term survival and safety.
Safety Profile: The vaccine is safe and well-tolerated, with no DLT , no CRS, and no ICANS observed.
Efficacy Data: At the low-dose level, mPFS exceeds 13 months to date, significantly outperforming the 6.9-month mPFS reported for the STUFF regimen.

CDE IND Approval

Clinical Evidence: GBM

Global first: 5-year continuous treatment induced a potent and durable tumor-specific T-cell immune response in the patient, with GBM patient survival >7 years.

J Pharm Anal 2023

一 ABOUT US

一 Research

一 Products & Service

一 Newsroom

一 Contact us

WeChat Official Account